Novel stable analogues of the neurotensin C-terminal hexapeptide containing unnatural amino acids

Neurotensin (NT) (pGlu–Leu–Tyr–Glu–Asn–Lys–Pro–Arg–Arg–Pro–Tyr–Ile–Leu) exerts a dual function as a neurotransmitter/neuromodulator in the central nervous system and as a hormone/cellular mediator in periphery. This dual function of NT establishes a connection between brain and peripheral tissues th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Amino acids 2019-07, Vol.51 (7), p.1009-1022
Hauptverfasser: Magafa, Vassiliki, Matsoukas, Minos-Timotheos, Karageorgos, Vlasios, Dermitzaki, Eirini, Exarchakou, Revekka, Stylos, Evgenios Κ., Pardalos, Michail, Margioris, Andrew N., Varvounis, George, Tzakos, Andreas G., Spyroulias, Georgios A., Liapakis, George
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1022
container_issue 7
container_start_page 1009
container_title Amino acids
container_volume 51
creator Magafa, Vassiliki
Matsoukas, Minos-Timotheos
Karageorgos, Vlasios
Dermitzaki, Eirini
Exarchakou, Revekka
Stylos, Evgenios Κ.
Pardalos, Michail
Margioris, Andrew N.
Varvounis, George
Tzakos, Andreas G.
Spyroulias, Georgios A.
Liapakis, George
description Neurotensin (NT) (pGlu–Leu–Tyr–Glu–Asn–Lys–Pro–Arg–Arg–Pro–Tyr–Ile–Leu) exerts a dual function as a neurotransmitter/neuromodulator in the central nervous system and as a hormone/cellular mediator in periphery. This dual function of NT establishes a connection between brain and peripheral tissues that renders this peptide a central player in energy homeostasis. Many biological actions of NT are mediated through its interaction with three types of NT receptors (NTS receptors). Despite its role in energy homeostasis, NT has a short half-life that hampers further determination of the biological actions of this peptide and its receptors in brain and periphery. The short half-life of NT is due to the proteolytic degradation of its C-terminal side by several endopeptidases. Therefore, it is important to synthesize NT analogues with resistant bonds against metabolic deactivation. Based on these findings, we herein report the synthesis of ten linear, two cyclic and two dimeric analogues of NT with modifications in its structure that improve their metabolic stability, while retaining the ability to bind to NTS receptors. Modifications at position 11 (introduction of d -Tyrosine (OEthyl) [ d -Tyr(Et)] or d -1-naphtylalanine [ d -1-Nal] were combined with introduction of a l -Lysine or a d -Arginine at positions 8 or 9, and 1-[2-(aminophenyl)-2-oxoethyl]-1 H -pyrrole-2-carboxylic acid (AOPC) at positions 7 or 8, resulting in compounds NT4-NT21. AOPC is an unnatural amino acid with promise in applications as a building block for the synthesis of peptidomimetic compounds. To biologically evaluate these analogues, we determined their plasma stability and their binding affinities to type 1 NT receptor (NTS1), endogenously expressed in HT-29 cells, Among the fourteen NT analogues, compounds, NT5, NT6, and NT8, which have d -Tyr(Et) at position 11, bound to NTS1 in a dose–response manner and with relatively high affinity but still lower than that of the natural peptide. Despite their lower binding affinities compared to NT, the NT5, NT6, and NT8 exhibited a remarkably higher stability, as a result of their chemistry, which provides protection from enzymatic activity. These results will set the basis for the rational design of novel NT molecules with improved pharmacological properties and enhanced enzymatic stability.
doi_str_mv 10.1007/s00726-019-02741-2
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2231969053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2223139478</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-7a8c487856a1092d702d302dd636b7a35c214ee61f648dcb5a9b30edbf2ea7753</originalsourceid><addsrcrecordid>eNp90U2PFCEQBmBiNO64-gc8GBIvXlAKaGiOZuJXstGLnkl1d_Vsb3pgBNrov5d1Vk08eAAOPFWkeBl7CvIlSOlelbYpKyR4IZUzINQ9tgOje6HA-_tsJ732wpgOLtijUm6kBNWDfcguNEjnFdgdw4_pG628VBxW4hhxTYeNCk8zr9fEI205VYpliXwvKuXj0gi_pu94olNdJuJjihWXuMQD32LEuuUGsLnEcVym8pg9mHEt9OTuvGRf3r75vH8vrj69-7B_fSVGA74Kh_1oetd3FkF6NTmpJt3WZLUdHOpuVGCILMzW9NM4dOgHLWkaZkXoXKcv2Ytz31NOX9sINRyXMtK6YqS0laCUBm-97HSjz_-hN2nLbbBb1Zj2xvVNqbMacyol0xxOeTli_hFAhtsAwjmA0AIIvwIIqhU9u2u9DUea_pT8_vEG9BmUdhUPlP--_Z-2PwH8d5EU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2223139478</pqid></control><display><type>article</type><title>Novel stable analogues of the neurotensin C-terminal hexapeptide containing unnatural amino acids</title><source>MEDLINE</source><source>SpringerLink (Online service)</source><creator>Magafa, Vassiliki ; Matsoukas, Minos-Timotheos ; Karageorgos, Vlasios ; Dermitzaki, Eirini ; Exarchakou, Revekka ; Stylos, Evgenios Κ. ; Pardalos, Michail ; Margioris, Andrew N. ; Varvounis, George ; Tzakos, Andreas G. ; Spyroulias, Georgios A. ; Liapakis, George</creator><creatorcontrib>Magafa, Vassiliki ; Matsoukas, Minos-Timotheos ; Karageorgos, Vlasios ; Dermitzaki, Eirini ; Exarchakou, Revekka ; Stylos, Evgenios Κ. ; Pardalos, Michail ; Margioris, Andrew N. ; Varvounis, George ; Tzakos, Andreas G. ; Spyroulias, Georgios A. ; Liapakis, George</creatorcontrib><description>Neurotensin (NT) (pGlu–Leu–Tyr–Glu–Asn–Lys–Pro–Arg–Arg–Pro–Tyr–Ile–Leu) exerts a dual function as a neurotransmitter/neuromodulator in the central nervous system and as a hormone/cellular mediator in periphery. This dual function of NT establishes a connection between brain and peripheral tissues that renders this peptide a central player in energy homeostasis. Many biological actions of NT are mediated through its interaction with three types of NT receptors (NTS receptors). Despite its role in energy homeostasis, NT has a short half-life that hampers further determination of the biological actions of this peptide and its receptors in brain and periphery. The short half-life of NT is due to the proteolytic degradation of its C-terminal side by several endopeptidases. Therefore, it is important to synthesize NT analogues with resistant bonds against metabolic deactivation. Based on these findings, we herein report the synthesis of ten linear, two cyclic and two dimeric analogues of NT with modifications in its structure that improve their metabolic stability, while retaining the ability to bind to NTS receptors. Modifications at position 11 (introduction of d -Tyrosine (OEthyl) [ d -Tyr(Et)] or d -1-naphtylalanine [ d -1-Nal] were combined with introduction of a l -Lysine or a d -Arginine at positions 8 or 9, and 1-[2-(aminophenyl)-2-oxoethyl]-1 H -pyrrole-2-carboxylic acid (AOPC) at positions 7 or 8, resulting in compounds NT4-NT21. AOPC is an unnatural amino acid with promise in applications as a building block for the synthesis of peptidomimetic compounds. To biologically evaluate these analogues, we determined their plasma stability and their binding affinities to type 1 NT receptor (NTS1), endogenously expressed in HT-29 cells, Among the fourteen NT analogues, compounds, NT5, NT6, and NT8, which have d -Tyr(Et) at position 11, bound to NTS1 in a dose–response manner and with relatively high affinity but still lower than that of the natural peptide. Despite their lower binding affinities compared to NT, the NT5, NT6, and NT8 exhibited a remarkably higher stability, as a result of their chemistry, which provides protection from enzymatic activity. These results will set the basis for the rational design of novel NT molecules with improved pharmacological properties and enhanced enzymatic stability.</description><identifier>ISSN: 0939-4451</identifier><identifier>EISSN: 1438-2199</identifier><identifier>DOI: 10.1007/s00726-019-02741-2</identifier><identifier>PMID: 31079216</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Affinity ; Amino Acid Sequence ; Amino acids ; Amino Acids - chemistry ; Analytical Chemistry ; Arginine ; Binding ; Biochemical Engineering ; Biochemistry ; Biomedical and Life Sciences ; Brain ; Central nervous system ; Chemistry Techniques, Synthetic ; Chromatography, High Pressure Liquid ; Deactivation ; Energy balance ; Enzymatic activity ; Half-life ; Homeostasis ; HT29 Cells ; Humans ; Life Sciences ; Lysine ; Mass Spectrometry ; Metabolism ; Models, Molecular ; Molecular Dynamics Simulation ; Neurobiology ; Neuromodulation ; Neurotensin ; Neurotensin - chemistry ; Neurotrophin 4 ; Neurotrophin 5 ; Organic chemistry ; Original Article ; Peptides ; Peptidomimetics - chemical synthesis ; Peptidomimetics - metabolism ; Peptidomimetics - pharmacology ; Pharmacology ; Proteolysis ; Proteomics ; Receptors ; Receptors, Neurotensin - chemistry ; Solitary tract nucleus ; Stability analysis ; Synthesis ; Tyrosine</subject><ispartof>Amino acids, 2019-07, Vol.51 (7), p.1009-1022</ispartof><rights>Springer-Verlag GmbH Austria, part of Springer Nature 2019</rights><rights>Amino Acids is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-7a8c487856a1092d702d302dd636b7a35c214ee61f648dcb5a9b30edbf2ea7753</citedby><cites>FETCH-LOGICAL-c419t-7a8c487856a1092d702d302dd636b7a35c214ee61f648dcb5a9b30edbf2ea7753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00726-019-02741-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00726-019-02741-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31079216$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magafa, Vassiliki</creatorcontrib><creatorcontrib>Matsoukas, Minos-Timotheos</creatorcontrib><creatorcontrib>Karageorgos, Vlasios</creatorcontrib><creatorcontrib>Dermitzaki, Eirini</creatorcontrib><creatorcontrib>Exarchakou, Revekka</creatorcontrib><creatorcontrib>Stylos, Evgenios Κ.</creatorcontrib><creatorcontrib>Pardalos, Michail</creatorcontrib><creatorcontrib>Margioris, Andrew N.</creatorcontrib><creatorcontrib>Varvounis, George</creatorcontrib><creatorcontrib>Tzakos, Andreas G.</creatorcontrib><creatorcontrib>Spyroulias, Georgios A.</creatorcontrib><creatorcontrib>Liapakis, George</creatorcontrib><title>Novel stable analogues of the neurotensin C-terminal hexapeptide containing unnatural amino acids</title><title>Amino acids</title><addtitle>Amino Acids</addtitle><addtitle>Amino Acids</addtitle><description>Neurotensin (NT) (pGlu–Leu–Tyr–Glu–Asn–Lys–Pro–Arg–Arg–Pro–Tyr–Ile–Leu) exerts a dual function as a neurotransmitter/neuromodulator in the central nervous system and as a hormone/cellular mediator in periphery. This dual function of NT establishes a connection between brain and peripheral tissues that renders this peptide a central player in energy homeostasis. Many biological actions of NT are mediated through its interaction with three types of NT receptors (NTS receptors). Despite its role in energy homeostasis, NT has a short half-life that hampers further determination of the biological actions of this peptide and its receptors in brain and periphery. The short half-life of NT is due to the proteolytic degradation of its C-terminal side by several endopeptidases. Therefore, it is important to synthesize NT analogues with resistant bonds against metabolic deactivation. Based on these findings, we herein report the synthesis of ten linear, two cyclic and two dimeric analogues of NT with modifications in its structure that improve their metabolic stability, while retaining the ability to bind to NTS receptors. Modifications at position 11 (introduction of d -Tyrosine (OEthyl) [ d -Tyr(Et)] or d -1-naphtylalanine [ d -1-Nal] were combined with introduction of a l -Lysine or a d -Arginine at positions 8 or 9, and 1-[2-(aminophenyl)-2-oxoethyl]-1 H -pyrrole-2-carboxylic acid (AOPC) at positions 7 or 8, resulting in compounds NT4-NT21. AOPC is an unnatural amino acid with promise in applications as a building block for the synthesis of peptidomimetic compounds. To biologically evaluate these analogues, we determined their plasma stability and their binding affinities to type 1 NT receptor (NTS1), endogenously expressed in HT-29 cells, Among the fourteen NT analogues, compounds, NT5, NT6, and NT8, which have d -Tyr(Et) at position 11, bound to NTS1 in a dose–response manner and with relatively high affinity but still lower than that of the natural peptide. Despite their lower binding affinities compared to NT, the NT5, NT6, and NT8 exhibited a remarkably higher stability, as a result of their chemistry, which provides protection from enzymatic activity. These results will set the basis for the rational design of novel NT molecules with improved pharmacological properties and enhanced enzymatic stability.</description><subject>Affinity</subject><subject>Amino Acid Sequence</subject><subject>Amino acids</subject><subject>Amino Acids - chemistry</subject><subject>Analytical Chemistry</subject><subject>Arginine</subject><subject>Binding</subject><subject>Biochemical Engineering</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Brain</subject><subject>Central nervous system</subject><subject>Chemistry Techniques, Synthetic</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Deactivation</subject><subject>Energy balance</subject><subject>Enzymatic activity</subject><subject>Half-life</subject><subject>Homeostasis</subject><subject>HT29 Cells</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Lysine</subject><subject>Mass Spectrometry</subject><subject>Metabolism</subject><subject>Models, Molecular</subject><subject>Molecular Dynamics Simulation</subject><subject>Neurobiology</subject><subject>Neuromodulation</subject><subject>Neurotensin</subject><subject>Neurotensin - chemistry</subject><subject>Neurotrophin 4</subject><subject>Neurotrophin 5</subject><subject>Organic chemistry</subject><subject>Original Article</subject><subject>Peptides</subject><subject>Peptidomimetics - chemical synthesis</subject><subject>Peptidomimetics - metabolism</subject><subject>Peptidomimetics - pharmacology</subject><subject>Pharmacology</subject><subject>Proteolysis</subject><subject>Proteomics</subject><subject>Receptors</subject><subject>Receptors, Neurotensin - chemistry</subject><subject>Solitary tract nucleus</subject><subject>Stability analysis</subject><subject>Synthesis</subject><subject>Tyrosine</subject><issn>0939-4451</issn><issn>1438-2199</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp90U2PFCEQBmBiNO64-gc8GBIvXlAKaGiOZuJXstGLnkl1d_Vsb3pgBNrov5d1Vk08eAAOPFWkeBl7CvIlSOlelbYpKyR4IZUzINQ9tgOje6HA-_tsJ732wpgOLtijUm6kBNWDfcguNEjnFdgdw4_pG628VBxW4hhxTYeNCk8zr9fEI205VYpliXwvKuXj0gi_pu94olNdJuJjihWXuMQD32LEuuUGsLnEcVym8pg9mHEt9OTuvGRf3r75vH8vrj69-7B_fSVGA74Kh_1oetd3FkF6NTmpJt3WZLUdHOpuVGCILMzW9NM4dOgHLWkaZkXoXKcv2Ytz31NOX9sINRyXMtK6YqS0laCUBm-97HSjz_-hN2nLbbBb1Zj2xvVNqbMacyol0xxOeTli_hFAhtsAwjmA0AIIvwIIqhU9u2u9DUea_pT8_vEG9BmUdhUPlP--_Z-2PwH8d5EU</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Magafa, Vassiliki</creator><creator>Matsoukas, Minos-Timotheos</creator><creator>Karageorgos, Vlasios</creator><creator>Dermitzaki, Eirini</creator><creator>Exarchakou, Revekka</creator><creator>Stylos, Evgenios Κ.</creator><creator>Pardalos, Michail</creator><creator>Margioris, Andrew N.</creator><creator>Varvounis, George</creator><creator>Tzakos, Andreas G.</creator><creator>Spyroulias, Georgios A.</creator><creator>Liapakis, George</creator><general>Springer Vienna</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PDBOC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190701</creationdate><title>Novel stable analogues of the neurotensin C-terminal hexapeptide containing unnatural amino acids</title><author>Magafa, Vassiliki ; Matsoukas, Minos-Timotheos ; Karageorgos, Vlasios ; Dermitzaki, Eirini ; Exarchakou, Revekka ; Stylos, Evgenios Κ. ; Pardalos, Michail ; Margioris, Andrew N. ; Varvounis, George ; Tzakos, Andreas G. ; Spyroulias, Georgios A. ; Liapakis, George</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-7a8c487856a1092d702d302dd636b7a35c214ee61f648dcb5a9b30edbf2ea7753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Affinity</topic><topic>Amino Acid Sequence</topic><topic>Amino acids</topic><topic>Amino Acids - chemistry</topic><topic>Analytical Chemistry</topic><topic>Arginine</topic><topic>Binding</topic><topic>Biochemical Engineering</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Brain</topic><topic>Central nervous system</topic><topic>Chemistry Techniques, Synthetic</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Deactivation</topic><topic>Energy balance</topic><topic>Enzymatic activity</topic><topic>Half-life</topic><topic>Homeostasis</topic><topic>HT29 Cells</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Lysine</topic><topic>Mass Spectrometry</topic><topic>Metabolism</topic><topic>Models, Molecular</topic><topic>Molecular Dynamics Simulation</topic><topic>Neurobiology</topic><topic>Neuromodulation</topic><topic>Neurotensin</topic><topic>Neurotensin - chemistry</topic><topic>Neurotrophin 4</topic><topic>Neurotrophin 5</topic><topic>Organic chemistry</topic><topic>Original Article</topic><topic>Peptides</topic><topic>Peptidomimetics - chemical synthesis</topic><topic>Peptidomimetics - metabolism</topic><topic>Peptidomimetics - pharmacology</topic><topic>Pharmacology</topic><topic>Proteolysis</topic><topic>Proteomics</topic><topic>Receptors</topic><topic>Receptors, Neurotensin - chemistry</topic><topic>Solitary tract nucleus</topic><topic>Stability analysis</topic><topic>Synthesis</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magafa, Vassiliki</creatorcontrib><creatorcontrib>Matsoukas, Minos-Timotheos</creatorcontrib><creatorcontrib>Karageorgos, Vlasios</creatorcontrib><creatorcontrib>Dermitzaki, Eirini</creatorcontrib><creatorcontrib>Exarchakou, Revekka</creatorcontrib><creatorcontrib>Stylos, Evgenios Κ.</creatorcontrib><creatorcontrib>Pardalos, Michail</creatorcontrib><creatorcontrib>Margioris, Andrew N.</creatorcontrib><creatorcontrib>Varvounis, George</creatorcontrib><creatorcontrib>Tzakos, Andreas G.</creatorcontrib><creatorcontrib>Spyroulias, Georgios A.</creatorcontrib><creatorcontrib>Liapakis, George</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Databases</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Materials science collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Amino acids</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Magafa, Vassiliki</au><au>Matsoukas, Minos-Timotheos</au><au>Karageorgos, Vlasios</au><au>Dermitzaki, Eirini</au><au>Exarchakou, Revekka</au><au>Stylos, Evgenios Κ.</au><au>Pardalos, Michail</au><au>Margioris, Andrew N.</au><au>Varvounis, George</au><au>Tzakos, Andreas G.</au><au>Spyroulias, Georgios A.</au><au>Liapakis, George</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel stable analogues of the neurotensin C-terminal hexapeptide containing unnatural amino acids</atitle><jtitle>Amino acids</jtitle><stitle>Amino Acids</stitle><addtitle>Amino Acids</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>51</volume><issue>7</issue><spage>1009</spage><epage>1022</epage><pages>1009-1022</pages><issn>0939-4451</issn><eissn>1438-2199</eissn><abstract>Neurotensin (NT) (pGlu–Leu–Tyr–Glu–Asn–Lys–Pro–Arg–Arg–Pro–Tyr–Ile–Leu) exerts a dual function as a neurotransmitter/neuromodulator in the central nervous system and as a hormone/cellular mediator in periphery. This dual function of NT establishes a connection between brain and peripheral tissues that renders this peptide a central player in energy homeostasis. Many biological actions of NT are mediated through its interaction with three types of NT receptors (NTS receptors). Despite its role in energy homeostasis, NT has a short half-life that hampers further determination of the biological actions of this peptide and its receptors in brain and periphery. The short half-life of NT is due to the proteolytic degradation of its C-terminal side by several endopeptidases. Therefore, it is important to synthesize NT analogues with resistant bonds against metabolic deactivation. Based on these findings, we herein report the synthesis of ten linear, two cyclic and two dimeric analogues of NT with modifications in its structure that improve their metabolic stability, while retaining the ability to bind to NTS receptors. Modifications at position 11 (introduction of d -Tyrosine (OEthyl) [ d -Tyr(Et)] or d -1-naphtylalanine [ d -1-Nal] were combined with introduction of a l -Lysine or a d -Arginine at positions 8 or 9, and 1-[2-(aminophenyl)-2-oxoethyl]-1 H -pyrrole-2-carboxylic acid (AOPC) at positions 7 or 8, resulting in compounds NT4-NT21. AOPC is an unnatural amino acid with promise in applications as a building block for the synthesis of peptidomimetic compounds. To biologically evaluate these analogues, we determined their plasma stability and their binding affinities to type 1 NT receptor (NTS1), endogenously expressed in HT-29 cells, Among the fourteen NT analogues, compounds, NT5, NT6, and NT8, which have d -Tyr(Et) at position 11, bound to NTS1 in a dose–response manner and with relatively high affinity but still lower than that of the natural peptide. Despite their lower binding affinities compared to NT, the NT5, NT6, and NT8 exhibited a remarkably higher stability, as a result of their chemistry, which provides protection from enzymatic activity. These results will set the basis for the rational design of novel NT molecules with improved pharmacological properties and enhanced enzymatic stability.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>31079216</pmid><doi>10.1007/s00726-019-02741-2</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0939-4451
ispartof Amino acids, 2019-07, Vol.51 (7), p.1009-1022
issn 0939-4451
1438-2199
language eng
recordid cdi_proquest_miscellaneous_2231969053
source MEDLINE; SpringerLink (Online service)
subjects Affinity
Amino Acid Sequence
Amino acids
Amino Acids - chemistry
Analytical Chemistry
Arginine
Binding
Biochemical Engineering
Biochemistry
Biomedical and Life Sciences
Brain
Central nervous system
Chemistry Techniques, Synthetic
Chromatography, High Pressure Liquid
Deactivation
Energy balance
Enzymatic activity
Half-life
Homeostasis
HT29 Cells
Humans
Life Sciences
Lysine
Mass Spectrometry
Metabolism
Models, Molecular
Molecular Dynamics Simulation
Neurobiology
Neuromodulation
Neurotensin
Neurotensin - chemistry
Neurotrophin 4
Neurotrophin 5
Organic chemistry
Original Article
Peptides
Peptidomimetics - chemical synthesis
Peptidomimetics - metabolism
Peptidomimetics - pharmacology
Pharmacology
Proteolysis
Proteomics
Receptors
Receptors, Neurotensin - chemistry
Solitary tract nucleus
Stability analysis
Synthesis
Tyrosine
title Novel stable analogues of the neurotensin C-terminal hexapeptide containing unnatural amino acids
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T18%3A54%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20stable%20analogues%20of%20the%20neurotensin%20C-terminal%20hexapeptide%20containing%20unnatural%20amino%20acids&rft.jtitle=Amino%20acids&rft.au=Magafa,%20Vassiliki&rft.date=2019-07-01&rft.volume=51&rft.issue=7&rft.spage=1009&rft.epage=1022&rft.pages=1009-1022&rft.issn=0939-4451&rft.eissn=1438-2199&rft_id=info:doi/10.1007/s00726-019-02741-2&rft_dat=%3Cproquest_cross%3E2223139478%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2223139478&rft_id=info:pmid/31079216&rfr_iscdi=true